CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT06642610
Status
Recruiting
Apply to this trial

Conditions

  • Cystic Fibrosis (CF)
  • Cystic Fibrosis-related Diabetes
  • Prediabetes

Eligibility Criteria

Sex
ALL
Age
12 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • CGM Dynamic Index (CDI) — DEVICE
    Participants will undergo one-time oral glucose tolerance test (OGTT) and a one-time use of a CGM device, which will be worn for up to 10 days.

Study Details

The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.

Key Dates

Start date
Jun 15, 2025
Status verified
Jul 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: CF without diabetes
    a person with cystic fibrosis and no diabetes
  • Other: CF with Prediabetes
    a person with cystic fibrosis and prediabetes

Primary Outcome Measure

CGM Dynamic Index (CDI) for predicting prediabetes in people with cystic fibrosis [ Time Frame: 10 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Health, University HospitalIndianapolisIndiana46202
Kathy Bohanan
[email protected]
317-278-0727

Find similar trials in Indianapolis, IN

By research site
Indiana University Health, University Hospital· Indianapolis, IN

Related Studies